Retrospective, observational data collection of the treatment of phenylketonuria in the UK, and associated clinical and health outcomes

References

• Treftz FK, Burton BK, Longo N, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: A phase III, randomized, double-blind, placebo-controlled study. J Pediatr 2009;154:700-7
   PubMed Web of Science ®Google Scholar
• The National Society for Phenylketonuria, UK. Management of PKU. NSPKU, 2004 http://www.nspku.org/Documents/Management%20of%20PKU.pdf [Last accessed 24 Sept 2010]
   Google Scholar
• Scriver CR, Kaufman S. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver CR, et al., Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill, 2001:1667-724
   Google Scholar
• Antshel KM, Waisbren SE. Timing is everything: executive functions in children exposed to elevated concentrations of phenylalanine. Neuropsychology 2003;17:458-68
   PubMed Web of Science ®Google Scholar
• Moyle JJ, Fox AM, Arthur M, et al. Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsych Rev 2007;17:91-101
   PubMed Web of Science ®Google Scholar
• Brumm VL, Azen C, Moats RA, et al. Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review. J Inherit Metab Dis 2004;27:549-66
   PubMed Web of Science ®Google Scholar
• National Electronic Library for Medicines entry: Sapropterin APC/DTC briefing document. Published by London New Drugs Group, October 2008. Available at: http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews/Sapropterin-Kuvan/ [Last accessed 24 Sept 2010]
   Google Scholar
• National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: Phenylketonuria: screening and management, October 16-18, 2000. Pediatrics 2001;108:972-82
   PubMed Web of Science ®Google Scholar
• Loeber JG. Neonatal screening in Europe; the situation in 2004. J Inherit Metab Dis 2007;30:430-8
   PubMed Web of Science ®Google Scholar
• Shortland GJ. BIMDG - Inherited Inborn Errors of Metabolism – A Service Vision for Setting Standards of Care. Available at: http://www.bimdg.org.uk/downloads/BIMDG_Vision.pdf [Last accessed 24 Sept 2010]
   Google Scholar
• Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010;376:1417-27
   PubMed Web of Science ®Google Scholar
• Ozalp I, Coskun T, Tokatli A, et al. Newborn PKU screening in Turkey: at present and organization for future. Turk J Pediatr 2001;43:97-101
   PubMed Web of Science ®Google Scholar
• Trefz FK, Belanger-Quintana A. Sapropterin dihydrochloride: a new drug and a new concept in the management of phenylketonuria. Drugs Today (Barc) 2010;46:589-600
   PubMed Web of Science ®Google Scholar
• Guldberg P, Henriksen KF, Sipila I, et al. Phenylketonuria in a low incidence population: molecular characterisation of mutations in Finland. J Med Genet 1995;32:976-8
   PubMed Web of Science ®Google Scholar
• Rylance G. Outcome of early detected and early treated phenylketonuria subjects. Postgrad Med J 1989;65:S7-9
   PubMed Web of Science ®Google Scholar
• MacDonald A. Diet and compliance in phenylketonuria. Eur J Pediatrics 2000;159:136-41
   PubMed Web of Science ®Google Scholar
• Levy HL, Milanowski A, Chakrapani A, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in subjects with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007;370:504-10
   PubMed Web of Science ®Google Scholar
• Koch R, Burton B, Hoganson G, et al. Phenylketonuria in adulthood: a collaborative study. J Inherit Metab Dis 2002;25:333-46
   PubMed Web of Science ®Google Scholar
• Walter JH, White FJ, Hall SK, et al. How practical are recommendations for dietary control in phenylketonuria? Lancet 2002;360:55-7
   PubMed Web of Science ®Google Scholar
• Gokmen-Ozel H, Ahring K, Belanger-Quintana A, et al. Blood phenylalanine control in PKU: a survey of ten European centres. Poster Abstract 219 ICIEM 2009
   Google Scholar
• Waisbren SE, Noel K, Fahrbach K, et al. Phenylalanine blood concentrations and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Gen Metab 2007;92:63-70
   PubMed Web of Science ®Google Scholar
• DeRoche K, Welsh M. Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function. Dev Neuropsychol 2008;33:474-504
   PubMed Web of Science ®Google Scholar
• Gentille JK, Ten Hoedt AE, Bosch AM. Psychosocial aspects of PKU: hidden disabilities – a review. Mol Genet Metab 2010;99:S64-7
   PubMed Web of Science ®Google Scholar
• Waisbren SE, Mahon BE, Schnell RR, et al. Predictors of intelligence quotient and intelligence quotient change in persons treated for phenylketonuria early in life. Pediatrics 1987;79:351-5
   PubMed Web of Science ®Google Scholar
• Albrecht J, Garbade SF, Burgard P. Neuropsychological speed tests and blood phenylalanine concentrations in subjects with phenylketonuria: a meta-analysis. Neurosc Biobehav Rev 2009;33:414-21
   PubMed Web of Science ®Google Scholar
• Welsh MC, Pennington BF, Ozonoff S, et al. Neuropsychology of early-treated phenylketonuria: specific executive function deficits. Child Dev 1990;61:1697-713
   PubMed Web of Science ®Google Scholar
• Anderson VA, Anderson P, Northam E, et al. Relationships between cognitive and behavioural measures of executive function in children with brain disease. Child Neuropsychol 2002;8:231-40
   PubMed Web of Science ®Google Scholar
• Channon S, Goodman G, Zlotowitz S, et al. Effects of dietary management of phenylketonuria on long-term cognitive outcome. Arch Dis Child 2009;2:213-18
   Google Scholar
• Huijbregts SC, de Sonneville LM, Licht R, et al. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia 2002;40:7-15
   PubMed Web of Science ®Google Scholar
• Macdonald A, Rylance G, Davies P, et al. Administration of protein substitute and quality of control in phenylketonuria: a randomized study. J Inherit Metab Dis 2003;26:319-26
   PubMed Web of Science ®Google Scholar
• ICD9Data.com. 2011 ICD-9-CM Diagnosis Code 270.1. 2011. Available at: URL: http://www.icd9data.com/2011/Volume1/240-279/270-279/270/270.1.htm [Last accessed 15 February 2011]
   Google Scholar
• SAS Institute Inc. (2008). SAS Proprietary Software 9.2 (TS2MO). Copyright 2002–2008 SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA
   Google Scholar
• Von Elm E, Altman DG, Egger M et al., for the STROBE Initiative (2007). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLoS Med 4: e296. doi:10.1371/journal.pmed.0040296. Available at: http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0040296 [Last accessed 24 Sept 2010]
   Google Scholar
• Koch R, Trefz F, Waisbren S. Psychosocial issues and outcomes in maternal PKU. Mol Gen Metab 2010;99:S68-74
   PubMed Web of Science ®Google Scholar